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Introduction {#sec1}
============

Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant genetic disorder in which acute inflammation may trigger the formation of a second skeleton of heterotopic bone. Classic FOP is caused by gain-of-function mutation (617G \> A; R206H) in the activin receptor-like kinase 2 (ACVR1/ALK2) gene, encoding the bone morphogenetic protein (BMP) type I receptor ([@bib18]). Enhanced BMP signaling in patients with the ALK2 R206H mutation has been attributed to loss of inhibitory activity of the ALK2-interacting protein FK506-binding protein-12 (FKBP12) ([@bib3], [@bib22]). Previous publications indicated that Tie2^+^ endothelial cells (ECs) and mesenchymal cells (MCs) contributed as progenitor cells to the episodic heterotopic ossification (HO) in FOP ([@bib14], [@bib24]). Other cells like circulating osteogenic precursors, skeletal myoblasts, and vascular smooth muscle cells also were found in FOP lesions and may contribute to HO in FOP ([@bib5], [@bib10], [@bib20]).

Despite recent advances in understanding of the disease ([@bib4]), to date there is no cure or even treatment for HO in FOP. A comprehensive understanding of the molecular mechanisms underlying abnormal behavior of bone-forming progenitor cells in FOP could be one approach toward effective treatment for HO in FOP, and to other more prevalent situations with HO that, for example, may occur after traumatic accidents or deep tissue burns. The traditional way of obtaining human biopsy tissues from FOP patients is limited as physical and surgical injury can induce HO. New protocols to produce well-characterized FOP bone-forming progenitor cells for research and therapeutic drug screening are needed. The ability to generate human induced pluripotent stem cells (hiPSCs) ([@bib21]) from adult tissues provides new opportunities for research on FOP. If derived from patients with genetic disease, hiPSCs allow production of large numbers of diseased target cells for basic research and drug development since they are immortal and pluripotent ([@bib19]).

In this study, we generated FOP hiPSCs from kidney cells isolated from urine by episomal vectors. The expression of pluripotent markers and ability to form derivatives of the three germ layers were comparable in FOP and control hiPSCs. However, the mutation in ALK2 reduced the efficiency of differentiation of hiPSCs into ECs and affected the phenotypes of ECs and pericytes. The hiPSC-derived ECs (hiPSC-ECs) from FOP patients exhibited reduced expression of vascular endothelial growth factor receptor 2 (VEGFR2) and could be transformed into MCs through endothelial-mesenchymal transition (EndMT). The hiPSC-derived pericytes (hiPSC-pericytes) from the FOP group showed increased ability to mineralize compared with the control. Our experiments demonstrated that disease-relevant cells differentiated from FOP hiPSCs possessed phenotypes reminiscent of the FOP disease.

Results {#sec2}
=======

Generation of FOP hiPSCs from Urine Cells {#sec2.1}
-----------------------------------------

We used a rapid and non-invasive procedure to isolate kidney cells in urine from FOP patients ([@bib26]). The cells were isolated from 50--100 ml middle stream of the micturition from two male FOP patients (Dutch and Chinese, F2 and F3) diagnosed with the classic R206H mutation and two healthy male donors (Dutch and Chinese, C2 and C3) ([Figure S1](#mmc1){ref-type="supplementary-material"}B).

A schematic representation of hiPSC generation is shown in [Figure S1](#mmc1){ref-type="supplementary-material"}A. In summary, cultured cells from urine were electroporated with episomal vectors containing *OCT4*, *SOX2*, *KLF4*, and the *pCEP4*-*miR*-*302*-*367* cluster (containing *miR*-*302b*, *c*, *a*, *d*, and *miR*-*367*) ([@bib26]). Transfected urine cells were maintained in serum-free mTesR1 medium supplemented with a cocktail of small molecule inhibitors to promote reprogramming: CHIR99021, PD0325901, A83-01, and thiazovivin ([@bib23]). Small colonies of cells appeared that progressively adopted a human embryonic stem cell (hESC)-like morphology. Selected hiPSCs were picked manually and expanded at day 20; hiPSCs maintained their hESC-like morphology with prominent nuclei and little cytoplasm and stained positive for alkaline phosphatase (ALP) ([Figure S1](#mmc1){ref-type="supplementary-material"}B).

The hiPSCs from one healthy donor (C3) and from two FOP patients (F2 and F3) were characterized; the other control hiPSC line (UE017C1) was obtained from the Guangzhou Stem Cell Bank produced by the same method and was characterized previously ([@bib26]). The presence of classical mutation in the *ALK2* gene was confirmed in FOP hiPSCs ([Figure S1](#mmc1){ref-type="supplementary-material"}C). FOP and control hiPSC karyotypes were checked before passage 10 and these were normal ([Figure S1](#mmc1){ref-type="supplementary-material"}D). The loss of exogenous reprogramming factors and episomal backbones was demonstrated by genomic PCR that specifically amplifies exogenous factors ([Figure S1](#mmc1){ref-type="supplementary-material"}E). The quantitative real-time PCR analysis revealed that, compared to urine cells, FOP hiPSCs had upregulated expression of endogenous hESC transcriptional genes (endogenous *OCT4*, endogenous *SOX2*, *NANOG*, and *REX1*), and they had expression levels comparable with established H1 hESCs ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Immunofluorescence microscopy showed expression of pluripotency-associated antigens OCT4, SSEA-4, TRA-1-60, and TRA-1-81 ([Figure S1](#mmc1){ref-type="supplementary-material"}G). In addition, hiPSCs formed teratomas in mice in vivo, confirming the pluripotency of FOP iPSCs ([Figure S1](#mmc1){ref-type="supplementary-material"}H). Therefore, hiPSCs from FOP patients corresponded phenotypically and functionally to hESCs.

Impaired EC Differentiation of FOP hiPSCs {#sec2.2}
-----------------------------------------

A slight elevation of pSMAD1/5 signaling in FOP hiPSCs compared to control hiPSCs was observed when these cells were cultured for 24 hr in medium with low serum concentrations, but not in the undifferentiated FOP iPSCs ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}I). We differentiated hiPSCs into ECs and pericytes to examine how minor changes in ALK2 R206H/SMAD signaling influenced the fate of two possible progenitor cells of FOP, i.e., ECs and pericytes. On days 10--12 of differentiation, flow cytometry (fluorescence-activated cell sorting \[FACS\]) analysis showed that two cell populations formed as follows: CD31^+^ ECs and platelet-derived growth factor receptor (PDGFR) β^+^ pericytes ([Figure 1](#fig1){ref-type="fig"}B). The generation of CD31^+^/VE-cadherin^+^ cells was significantly impaired in FOP hiPSCs compared with controls, while general mesoderm induction was slightly enhanced in FOP hiPSCs ([Figures 1](#fig1){ref-type="fig"}B and 1C).

To verify the FACS data, we examined the expression of early mesoderm and EC-specific genes ([Figure 1](#fig1){ref-type="fig"}D). Differentiation resulted in efficient downregulation of pluripotent markers (*OCT4* and *NANOG*) in the control and FOP hiPSCs. Primitive streak/mesoderm lineage markers (*T* and *PDGFRα*) were upregulated in FOP hiPSCs on day 4 of differentiation, which may due to the positive effect of the BMP-signaling pathway on mesoderm formation. The induction of the early endothelial transcription factor (*ETV2*) on day 4 was similar between the two groups. However, consistent with the FACS data, we observed that endothelial-specific genes (*CD31* and *CD105*) were downregulated in FOP hiPSCs on day 7 of differentiation. Early pericyte markers *PDGFRβ* and *NG2* proteoglycan were expressed more abundantly in differentiating FOP hiPSCs. Overall, we observed that the EC differentiation efficiency was impaired while general mesoderm differentiation was enhanced in FOP hiPSCs; this difference may due to the elevated level of ALK2 R206H/SMAD signaling in FOP compared to control hiPSCs.

Characterization of FOP hiPSC-ECs {#sec2.3}
---------------------------------

Differentiated cell populations were divided into CD31^+^ ECs and CD31^−^ cells by CD31 antibody-coupled magnetic bead sorting ([Figure 2](#fig2){ref-type="fig"}A). The expression levels of BMP type I receptors ALK1 and ALK2 were not different in control versus FOP CD31^+^ cells ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Sorted FOP hiPSC-ECs were more sensitive to low concentrations of BMP6 (5 ng/ml) and the activated BMP signaling could be inhibited by BMP type I receptor kinase inhibitor LDN-193189 ([@bib27]; [Figure 2](#fig2){ref-type="fig"}B). FOP hiPSC-ECs exhibited poor viability and increased expression of senescence-associated β-galactosidase expression compared to controls ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). As the VEGF-signaling pathway is known to regulate survival and proliferation of ECs through VEGFR2 ([@bib6]), we found that the expression of VEGFR2 was lower in FOP hiPSC-ECs compared with the control by FACS analysis, while the expression levels of other EC genes (CD31 and VE-cadherin) were unchanged ([Figure 2](#fig2){ref-type="fig"}C). The lower expression of VEGFR2 may be responsible for the failure of FOP hiPSC-ECs to propagate in vitro, and this may be related to the activated BMP/SMAD signaling in these cells ([Figure 2](#fig2){ref-type="fig"}B).

Moreover, we observed that ECs cultured in EGM-2 medium with 2% serum showed increased expression of EndMT markers (*SLUG*, *N*-*cadherin*, and *TWIST*; [Figure 2](#fig2){ref-type="fig"}D) and lost the expression of endothelial-specific markers confirmed by quantitative real-time PCR (*VE*-*cadherin* and *VEGFR2*; [Figure 2](#fig2){ref-type="fig"}D) and FACS analysis (CD31, VE-cadherin, and VEGFR2; [Figure S2](#mmc1){ref-type="supplementary-material"}D). ECs turned to mesenchymal-like cells (EC-MCs) in EGM2 medium and the expression of mesenchymal markers CD73, CD90, and CD105 also were induced ([Figures 2](#fig2){ref-type="fig"}E, 2F, and [S2](#mmc1){ref-type="supplementary-material"}E). BMP signaling also was activated at an elevated level in FOP EC-MCs, as demonstrated by increased *ID1* expression ([Figure 2](#fig2){ref-type="fig"}G), a direct BMP/SMAD target gene ([@bib8]). Therefore, increased BMP signaling in FOP hiPSC-ECs correlates with impaired EC viability, increased senescence, and increased EndMT.

Activated BMP Signaling in FOP hiPSC-Pericytes {#sec2.4}
----------------------------------------------

The selected CD31^−^ cells were cultured in DMEM with 10% fetal bovine serum (FBS) or DMEM with 10% FBS supplemented with PDGF-BB and transforming growth factor (TGF) β3 for 1 day. The homogenous population expressed pericytes and MC markers (CD73, CD90, CD105, PDGFRβ, CD146, and NG2; [Figures 3](#fig3){ref-type="fig"}A, 3B, and [S3](#mmc1){ref-type="supplementary-material"}A). SMAD1/5 phosphorylation was increased in the FOP group in low-serum conditions, and this could be inhibited by LDN-193189 ([Figure 3](#fig3){ref-type="fig"}C). The mRNA expression level of *ALK2* was not different in control and FOP groups ([Figure S3](#mmc1){ref-type="supplementary-material"}B). The SMAD1/5 downstream target gene *ID1* also was significantly upregulated in the FOP group ([Figure 3](#fig3){ref-type="fig"}D). Thus, FOP hiPSC-pericytes exhibited elevated SMAD1/5 levels.

FOP hiPSC-Pericyte Mineralization as an Assay to Identify New ALK2 Inhibitors {#sec2.5}
-----------------------------------------------------------------------------

Heterotopic bone formation in FOP follows the progressive heterotopic endochondral ossification in soft connective tissues, a process in which condensing mesenchymal progenitor cells differentiate into chondrocytes and are eventually mineralized into osteoblasts and bone ([@bib11]). We examined the effect of ALK2 R206H mutation on chondrogenic differentiation by differentiating hiPSC-pericytes in the two-dimensional micromass culture system without the addition of growth factors. The hiPSC-pericytes were stained with Alcian blue for early differentiation and extracellular matrix production, such as glycosaminoglycans (GAGs) and sulfated GAGs. After 3 days of chondrocytic differentiation, Alcian blue staining indicated that FOP hiPSC-pericytes have more GAG expression than control hiPSC-pericytes ([Figures 4](#fig4){ref-type="fig"}A and 4B).

We further assessed the mineralization capability of FOP hiPSC-pericytes when grown in osteogenic medium. The osteoblast differentiation of pericytes was measured by determining ALP activity, an early marker of osteoblast differentiation. Histochemical staining revealed that ALP activity in the FOP group was enhanced ([Figure 4](#fig4){ref-type="fig"}C); F2-6 hiPSC-pericytes showed higher pSMAD1/5 signaling compared to F3-8 ([Figures 3](#fig3){ref-type="fig"}C and 3D), which may explain the stronger ALP activity in F2-6. Furthermore, we analyzed osteoblast differentiation by alizarin red S staining to detect calcium deposition. On day 21 and day 28 of differentiation, we detected higher mineralization in the FOP group ([Figures 4](#fig4){ref-type="fig"}D and 4E). Consistent with the ALP activity and alizarin red S staining, quantitative real-time PCR analysis confirmed that expression of osteoblast markers *ALP* and *OSTEOCALCIN* (*OSC*) ([Figure 4](#fig4){ref-type="fig"}F) was increased in the FOP group, but we did not detect altered expression of *COLLAGEN type I alpha 1 (COL1α)* in FOP and control cells ([Figure 4](#fig4){ref-type="fig"}F). Together these data indicate that FOP hiPSC-pericytes were prone to mineralization, which may be due to activated BMP/SMAD signal in these cells. After pretreating pericytes with LDN-212854, a BMP type I receptor kinase inhibitor that is more selective for ALK2 compared with other BMP type I receptors ([@bib15]), we observed that the ALP activity of FOP hiPSC-pericytes was partly inhibited ([Figure 4](#fig4){ref-type="fig"}G).

Discussion {#sec3}
==========

Our results demonstrated that hiPSCs could be used as an in vitro disease model for FOP. The hiPSC-ECs and hiPSC-pericytes can be applied to investigate the molecular mechanisms underlying the pathology of FOP, as well as to identify new therapeutic drugs.

We have shown that FOP hiPSCs could be established from cells in urine using non-integrating episomal vectors. BMP signaling contributes to the initial stage of iPSC reprogramming in mouse ([@bib17]), but induces differentiation of hESCs ([@bib25]). Consistent with prior research ([@bib12]), our FOP hiPSCs were generated without the addition of exogenous BMP inhibitors during the reprogramming process. We did not observe activated SMAD1/5 signaling in FOP hiPSCs maintained in hESC medium mTeSR1 unless these cells were placed in differentiation culture conditions. This may explain why FOP hiPSCs could be maintained and passaged in defined medium. Besides, we observed heterogeneous BMP/SMAD signaling and mineralization in FOP hiPSCs and derivative cells, indicating that intrinsic genetic and/or epigenetic features of donor cells may influence properties of hiPSCs and the progeny. To eliminate the heterogeneity, the isogenic correction FOP hiPSCs can help to facilitate more stringent screening for effects arising from clonal variations in hiPSCs ([@bib13]).

We found that the generation and maintenance of ECs from FOP hiPSCs were impaired. One explanation is the elevated BMP signaling in FOP hiPSC-ECs, which resulted in downregulation of VEGFR2 expression that mediated VEGF-induced proliferation and survival of ECs; this may have caused the decrease in EC viability. Inhibition of BMP receptor kinase activity by LDN-212854 during the vascular specification stage (from day 3 of hiPSC differentiation) did not rescue the impaired FOP hiPSC-EC phenotypes (unpublished data). BMPs are indispensable for the formation of mesoderm where ECs originate, but they may function as a context-dependent regulator in vascular morphogenesis ([@bib7]). In addition, a recent publication indicated activin A signals through the mutant ALK2 R206H to stimulate HO in FOP conditional-on knockin mice ([@bib4]). Of note, in our EC differentiation protocol, we used activin A and BMP4, both of which were shown to induce SMAD1/5 signaling through mutant ALK2 R206H ([@bib4]). These ligands may thus combine with the SMAD1/5 signal to contribute to the FOP hiPSC-EC phenotypes that we observed. The other explanation of low EC yields is the increased EndoMT in ALK2-mutated ECs. Consistent with a previous publication ([@bib14]), FOP EC-MCs showed higher expression of EndMT markers (*N*-*cadherin* and *TWIST*), which might be due to the interaction of mutant ALK2 R206H and VEGF signaling in these cells. Further investigation of the crosstalk between BMP signaling and VEGF signaling might contribute to the better understanding of the EndMT mechanism in FOP lesions and also help in identifying new drug-treatable targets to prevent HO in FOP patients.

Lastly, we demonstrated that the mutant ALK2 R206H contributed to the increased mineralization of FOP hiPSC-pericytes and, as such, is a useful human in vitro disease model for identifying and evaluating the bioactivity of ALK2 inhibitors. More evidence indicates that MCs are the major contributors of HO ([@bib24]), while ECs indirectly contribute to osteogenic differentiation by acting in a paracrine manner via crosstalk between ECs and MCs ([@bib2], [@bib9]). Even though Matsumoto et al. partly exhibited FOP phenotypes by directly differentiating hiPSCs into osteoblast cells ([@bib12]), they provided little evidence of how the specific cell types contributed to the increased mineralization. To further clarify the mineralization capacity of FOP hiPSCs in vitro, we differentiated hiPSCs into pericytes. ALP activity of FOP hiPSC-pericytes can be inhibited by pretreating with BMP inhibitor LDN-212854. As the ALP assay has been used as a high-throughput screening (HTS) readout for screening regulators in osteogenic differentiation ([@bib1]), our platform could be used for drug screening and further verifying the bioactivity of ALK2 inhibitors in the future.

Even though in this study we only studied ECs and pericytes, the two most well-known HO progenitor cells in FOP, it is possible other unidentified cells types also may be involved in the HO process in FOP. Due to the pluripotent characterization of hiPSCs, FOP hiPSCs can be differentiated into other (unknown) progenitor cells to discover the underlying molecular mechanisms of HO in the future.

Experimental Procedures {#sec4}
=======================

Primary human cells were obtained with informed consent. Experiments involving human subjects were approved by Institutional Review Board (IRB) GIBH-IRB02-2009002 at Guangzhou Institutes of Biomedicine and Health (GIBH) and 12/467 (2013 January) at VU University Medical Center. The animal research was approved by the IRB at GIBH (2010012). The generation and differentiation of hiPSCs were described previously ([@bib16], [@bib26]). Differences between the control group and the FOP group were evaluated by t test or one-way ANOVA with Tukey's multiple comparison tests (ns, not significant; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, and ^∗∗∗∗^p \< 0.0001). For further information, see the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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![Differentiation of FOP hiPSCs into ECs and Pericytes\
(A) Total SMAD1/5 and phospho-SMAD1/5 (pSMAD1/5) level in control hiPSCs (C3-3 and UE017C1) and FOP hiPSCs (F2-6 and F3-8). Note that the antibodies used here also may recognize SMAD8 and pSMAD8 bands.\
(B) FACS analysis of EC marker (CD31) or pericyte marker (PDGFRβ) expression at differentiation days 10--12 is shown.\
(C) Quantification of the FACS analysis data for relative percentage of CD31 and VE-cadherin double-positive ECs and PDGFRβ-positive pericytes. All values were adjusted to the control colony C3-3, which is defined as 1.\
(D) Relative gene expression at different time points during the differentiation. *ACTIN* was used to normalize gene expression.\
Data are presented as mean and SD from three independent experiments in (A), (C), and (D).](gr1){#fig1}

![ECs Derived from hiPSCs Undergo EndMT\
(A) Schematic representation shows EC and pericyte derivation from hiPSCs.\
(B) Analysis of relative expression of *ID1* in hiPSC-ECs is shown.\
(C) (Left) Representative FACS analysis for EC markers in hiPSC-ECs is shown. Blue, unstained cells; gray, antibody as indicated. (Right) Median fluorescence intensity of EC markers expression in hiPSC-ECs is shown.\
(D) Relative gene expression analysis of EC and EndMT markers in ECs and EC-MCs is shown.\
(E) Bright-field images of ECs and EC-MCs in the healthy donor (C3-3) and FOP patient (F3-8) are shown. Scale bar, 100 μm.\
(F) Percentages of CD73-, CD90-, and CD105-positive cells in EC-MCs. Representative FACS plots of CD73, CD90, and CD105 are shown in [Figure S2](#mmc1){ref-type="supplementary-material"}E.\
(G) Relative expression of *ID1* in EC-MCs is shown.\
Data are presented as mean and SD from three independent experiments in (B), (C), (D), (F), and (G). The quantitative real-time PCR results in (B), (D), and (G) were normalized to *ACTIN*. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Activated BMP Signaling in FOP hiPSC-Pericytes\
(A) Percentages of CD73-, CD90-, CD105-, PDGFRβ-, CD146-, and NG2-positive cells in hiPSC-pericytes. Representative FACS plots of CD73, CD90, CD105, PDGFRβ, CD146, and NG2 are shown in [Figure S3](#mmc1){ref-type="supplementary-material"}A.\
(B) Bright-field images of pericytes from healthy donor (UE017C1) and FOP patient (F3-8) are shown. Scale bar, 100 μm.\
(C) Western blot results showing SMAD1/5 phosphorylation in the hiPSC-pericytes. GAPDH was used as the loading control.\
(D) Relative expression of *ID1*. All experiments were normalized to *ACTIN*.\
Data are presented as mean and SD from three independent experiments in (C) and (D); the average of four independent experiments is shown in (A). See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Increased Mineralization of FOP hiPSC-Pericytes\
(A) Representative Alcian blue staining of the micromass for 3 days chondrogenic differentiation is shown. Scale bar, 2 mm.\
(B) Alcian blue staining of micromasses was quantified by stain extraction and absorbance reading at 595 nm.\
(C) ALP staining was performed 14 days (D14) after maintaining in α-MEM with 10% FBS (Ctrl) and osteogenic medium (OM). Results are shown as representative scanned images (left) and images taken at 4× magnification (right). Scale bar, 200 μm.\
(D) The mineralization was visualized by 2% alizarin red S staining on day 21 (D21) and day 28 (D28). Results are shown as representative scanned images (left) and images taken at 4× magnification (right). Scale bar, 200 μm.\
(E) Alizarin red S staining on D21 and D28 was quantified by stain extraction and absorbance reading at 570 nm.\
(F) Relative gene expression analysis of *ALP*, *COL1α*, and *OSC* on day 14 and day 28 of osteoblast differentiation. All experiments were normalized to *ACTIN*. Control, the average of the results from C3-3 and UE017C1; FOP, the average of the results from F2-6 and F3-8.\
(G) ALP assay on day 7 of F3-8 after maintaining in OM pretreated with LDN-212854 is shown.\
Data are presented as mean and SD from four times independent experiments in (E) and three times in (B) and (G).](gr4){#fig4}
